INS and melanoma: Follow-up was arranged with Endocrinology for the optimisation of the insulin regimen and further evaluation, including assessment of pituitary and adrenal function post-discharge to monitor for additional immune-related endocrinopathies; with the Diabetes Specialist Team to provide structured education and ongoing support in insulin management; and with Oncology services to evaluate the risk-benefit profile of continuing pembrolizumab therapy and to guide subsequent management strategies for melanoma.